A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment - Followed by an Open-Label Crossover Extension Study Comprising Subcutaneous and Intravenous Natalizumab Administration
Sponsor: Biogen
Listed as NCT03689972, this PHASE3 trial focuses on Multiple Sclerosis, Relapsing-Remitting and remains completed. Sponsored by Biogen, it has been updated 20 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
20 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2023 — Feb 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 15 earlier versions
-
Apr 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
-
Dec 2019 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
-
Oct 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — Oct 2019 [monthly]
Recruiting PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Atlanta, United States , Aurora, United States , Bamberg, Germany , Berlin, Germany , Bochum, Germany , Bordeaux, France , Box Hill, Australia , Breda, Netherlands , Brussels, Belgium , Burlington, United States and 89 more locations